Second-line docetaxel benefits seen for esophagogastric cancers
FROM A PRESS BRIEFING SPONSORED BY THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Dr. Ford and his associates now are analyzing cost-effectiveness data collected during the study.
Approximately 39,000 new cases of esophagogastric cancer are diagnosed each year in the United States and 1.5 million cases worldwide, most commonly adenocarcinomas. All patients with esophagogastric adenocarcinoma who present with advanced disease and 60%-70% of patients who present with local disease will relapse after first-line chemotherapy.
The gastrointestinal cancers meeting, where Dr. Ford will present the results, is cosponsored by ASCO, the American Gastroenterological Association Institute, the American Society for Radiation Oncology, and the Society of Surgical Oncology.
The charity Cancer Research UK funded the study. Sanofi-Aventis, which makes docetaxel, provided the drug for free. Some of Dr. Ford’s associates in the study have been consultants or advisers to Sanofi and/or received honoraria or research funding from the company.
